Article
Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Oct 2021
Celik Emir, Samanci Nilay Sengul, Karadag Mehmet, Demirci Nebi Serkan, Cikman Duygu Ilke, Derin Sumeyra, Bedir Sahin, Degerli Ezgi, Oruc Kerem, Oztas Nihan Senturk, Demirelli Fuat Hulusi
Abstract excerpt
INTRODUCTION: Erlotinib is an effective treatment option for EGFR-mutant non-small cell lung cancer. It is important to predict patients who will respond better to erlotinib. We designed this study to investigate the effect of renal insufficiency (RI) on erlotinib treatment outcomes. METHODS: All patients receiving erlotinib were stratified into 3 groups. Group 1 consisted of non-RI subjects with classical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.